HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis

被引：0
|
作者：
Wu, F. [1 ]
Zeng, Y. [1 ]
Chen, L. [2 ,3 ,4 ]
Zhou, M. [5 ]
Zhao, X. [6 ]
Luo, Y. [7 ,8 ]
Wu, J. [9 ]
Zhao, L. [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China
[2] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Thorac Surg, Guangzhou, Peoples R China
[6] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[7] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Peoples R China
[8] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China
[9] Hunan Canc Hosp, Changsha, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
HIP1-ALK fusion; ALK inhibitor; non-small-cell lung cancer (NSCLC);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.04
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [1] HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib
    Wang, W.
    Xu, C.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Chen, Y.
    Fang, M.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1032 - S1032
  • [2] HIP1-ALK fusion variant in non-small-cell lung cancer and response to crizotinib: a case report and review of the literature
    Zhu, Youcai
    Liao, Xinghui
    Wang, Wenxian
    Xu, Chunwei
    Zhuang, Wu
    Du, Kaiqi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (05): : 5212 - 5216
  • [3] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [4] A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
    Jin, Y.
    Hu, X.
    Chen, M.
    Chen, Y.
    Shi, X.
    Yu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1952 - S1952
  • [5] Brigatinib effective in ALK-positive non-small-cell lung cancer
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (06): : E310 - E310
  • [6] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [7] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [8] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [9] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [10] Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
    Barrows, Stephanie M.
    Wright, Kelly
    Copley-Merriman, Catherine
    Kaye, James A.
    Chioda, Marc
    Wiltshire, Robin
    Torgersen, Knut Martin
    Masters, Elizabeth T.
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 11 - 20
12345